Today's Rundown Genentech pays Bicycle $30M upfront to form discovery-stage immuno-oncology pact Moderna wins bragging rights as it kick-starts first experimental coronavirus clinical trial Harvard, Guangzhou Institute nab $115M for fight against COVID-19 [Sponsored] Executive Interviews at J.P. Morgan 2020 Kahr raises $18M to test CD47 drug with Roche's Tecentriq IMV's T-cell programming treatment keeps ovarian cancer at bay in midphase study Karius nets $165M from SoftBank and more to power its infection genomics test Novartis' hot new eye drug Beovu tied to potential vision loss: experts Featured Story | | | Tuesday, February 25, 2020 Roche’s Genentech is paying $30 million (€28 million) upfront to work with Bicycle Therapeutics on the development of immuno-oncology therapies. Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones as the assets progress. |
|
|---|
|
| | Download a recent study highlighting the root of key challenges clinical operations professionals are struggling with to complete their oversight responsibilities and the important solutions this study reveals. Read Now >> |
Top Stories Tuesday, February 25, 2020 Moderna shares shot up a massive 18% after-hours last night on the fairly standard news that it was about to start a drug trial. Tuesday, February 25, 2020 Harvard University scientists are teaming up with the Guangzhou Institute of Respiratory Disease with a $115 million boost from the China Evergrande Group. Thursday, February 13, 2020 FierceBiotech sits down with some of the most informative industry leaders at JPM 2020. Tuesday, February 25, 2020 Kahr Medical has raised $18 million (€17 million) to take an anti-CD47 drug into the clinic. The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test as a single agent and in combination with Roche’s checkpoint inhibitor Tecentriq. Tuesday, February 25, 2020 IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study, shrinking the tumors of about half of the patients. The company is working with the FDA on a path toward a speedy approval for the treatment, which is given in combination with low-dose chemotherapy. Monday, February 24, 2020 Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s upcoming sequel to its technology-focused venture capital megafund. Monday, February 24, 2020 Novartis has touted early success for its new eye drug Beovu, but an alert tying the drug to potential vision loss might cause docs to balk when it comes to prescribing the medicine. The American Society of Retina Specialists issued a note Sunday night to members about 14 cases of retinal vasculitis for Beovu patients, 11 of which were occlusive retinal vasculitis that can lead to vision loss. Resources Sponsored by: The Kinetix Group Read about the innovative ways payers are making smart moves in the healthcare game. Sponsored by: Veeva Learn how data management teams at ICON, Bioforum, and Vertex Pharmaceuticals are creating the spec and casebook in a single step, reducing study build times and effort by over 50%. Sponsored by: H1 Biopharma companies don't want to go to market with a product no one knows about. H1 has homed in on the often time-consuming research and engagement phases that companies must ace for a successful launch, said Ariel Katz, co-founder of H1. Sponsored by: Research Solutions / Reprints Desk Inc. 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Accenture Kevin Julian, senior managing director of Accenture’s life sciences practice, recently sat down with FierceBiotech to discuss market trends and Accenture’s new technology platform, INTIENT. Sponsored by: Eagle Productivity Solutions Mediocre adoption rates aren’t due to poorly designed software or lazy users. They’re the result of how skills are trained. Achieve high adoption rates for Veeva, Workday, Microstrategy or any software platform by implementing the right methodology with a focus on behavior change. Sponsored by: Blue Matter Consulting White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done. Sponsored by: Medidata To conduct a successful trial, do you need to understand the global eConsent Regulatory landscape? Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. Molecular Med TRI-CON: Final Days to Register! March 1-4, 2020 | Moscone North Convention Center | San Francisco, CA BioBasics 101: The Biology of Biotech March 26-27, 2020 | Boston, MA Drug Discovery Chemistry – Choose from 45 Presentations from Top Pharma April 13-17, 2020 | San Diego, CA BioBasics 101: The Biology of Biotech April 16-17, 2020 | Philadelphia, PA Drug Development Immersion April 23-24, 2020 | Boston, MA 2nd Annual World Pharma Week: Driving Innovation in Drug R&D June 2-4, 2020 | Boston, MA BIO International Convention June 8-11, 2020 | San Diego, CA Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now and begin Pre-Boot Camp Preparation. | Take your new medicine development skills to the next level. | 